

# PUREVAX® Protocol



**A broad and flexible range** providing combinations for flexibility and convenience

	8 weeks	11-12 weeks*	1 year	2 year	3 year	4 year	5 year
Strictly Indoor							
Indoor/Outdoor							
Shelter Cats							

## The PUREVAX® fully flexible range\*\*



**Easy to Give**  
ISFM Approved



\* Where high levels of maternal antibodies against these diseases are expected, the primary vaccination course should be delayed until 12 weeks of age.

\*\*PUREVAX® rabies also available in 1ml.



**Boehringer  
Ingelheim**

# PUREVAX® Highlights



The only vaccine range\* to be given the International Society of Feline Medicine Easy to Give™ accreditation.



The only fully non-adjuvanted feline range and the only range available in 0.5ml\*.

Offers unique protection against calicivirus and herpesvirus.

- 1 week onset of immunity for rapid protection<sup>1</sup>
- up to 3 years duration of immunity<sup>2</sup>

Meets the recommendations of the 2024 WSAVA guidelines<sup>3</sup> for FeLV.

\*PUREVAX® rabies remains in 1ml and excluded from ISFM Easy to Give™ award.



0.5ml



1. Jas D, Aeberle C, Lacombe V, Guiot AL, Poulet H. Onset of immunity in kittens after vaccination with a non-adjuvanted vaccine against feline panleucopenia, feline calicivirus and feline herpesvirus. Vet J 2009;182:86-93. <https://doi.org/10.1016/j.tvjl.2008.05.025>.  
2. Jas D, Frances-Duvert V, Vernes D, Guigal PM, Poulet H. Three-year duration of immunity for feline herpesvirus and calicivirus evaluated in a controlled vaccination-challenge laboratory trial. Vet Microbiol 2015;177:123-31. <https://doi.org/10.1016/j.vetmic.2015.03.009>.  
3. Squires RA, Crawford C, Marcondes M, Whitley N. 2024 guidelines for the vaccination of dogs and cats - compiled by the Vaccination Guidelines Group (VGG) of the World Small Animal Veterinary Association (WSAVA). J Small Anim Pr 2024;65:277-316. <https://doi.org/10.1111/jsap.13718>.  
The PUREVAX® range contains a combination of the following active ingredients: attenuated feline rhinotracheitis herpesvirus (FHV F2 strain), inactivated feline calicivirus antigens (FCV 431 and G1 strains), attenuated Chlamydia felis (905 strain), attenuated feline panleucopenia virus (PLI IV), FeLV recombinant canarypox virus (vCP97). PUREVAX® Rabies contains Rabies recombinant canarypox virus (vCP65). PUREVAX® FeLV is indicated for active immunisation of cats of 8 weeks of age or older against feline leukaemia for the prevention of persistent viraemia and clinical signs of the related disease. PUREVAX® RC is indicated for active immunisation of cats aged 8 weeks and older: against feline viral rhinotracheitis to reduce clinical signs; and against calicivirus infection to reduce clinical signs. PUREVAX® RCP is indicated for active immunisation of cats aged 8 weeks and older: against feline viral rhinotracheitis to reduce clinical signs; against calicivirus infection to reduce clinical signs; against feline panleucopenia to prevent mortality and clinical signs; and against leukaemia to prevent persistent viraemia and clinical signs of the related disease. PUREVAX® RCPCh is indicated for active immunisation of cats aged 8 weeks and older: against feline viral rhinotracheitis to reduce clinical signs, against calicivirus infection to reduce clinical signs, against Chlamydia felis infection to reduce clinical signs and against feline panleucopenia to prevent mortality and clinical signs. PUREVAX® RCPCh FeLV is indicated for active immunisation of cats aged 8 weeks and older: against feline viral rhinotracheitis to reduce clinical signs; against calicivirus infection to reduce clinical signs; against Chlamydia felis infection to reduce clinical signs; against feline panleucopenia to prevent mortality and clinical signs; and against leukaemia to prevent persistent viraemia and clinical signs of the related disease. PUREVAX® Rabies is indicated for active immunisation of cats 12 weeks of age and older to prevent mortality due to rabies infection. UK: POM-V IE: POM. For information about side effects, precautions, warnings and contraindications please refer to the product packaging and package leaflet. Prescription decisions are for the person issuing the prescription alone. Further information available in the SPC or from Boehringer Ingelheim Animal Health UK Ltd, RG12 8YS, UK. UK Tel: 01344 746959 (sales) or 01344 746957 (technical), IE Tel: 01 291 3985 (all queries). PUREVAX® is a registered trademark of Boehringer Ingelheim Animal Health France SCS, used under licence.  
©2024 Boehringer Ingelheim Animal Health UK Ltd. All rights reserved. Date of preparation: AUGUST 2024. UI-PET-0135-2024. Use Medicines Responsibly.

